|
1
|
Ezzat S, Asa SL, Couldwell WT, Barr CE,
Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary
adenomas. Cancer. 101:613–619. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ironside JW: Best Practice No 172:
Pituitary gland pathology. J Clin Pathol. 56:561–568. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scanarini M and Mingrino S: Functional
classification of pituitary adenomas. Acta Neurochir (Wien).
52:195–202. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Korbonits M and Carlsen E: Recent clinical
and pathophysiological advances in non-functioning pituitary
adenomas. Horm Res. 71 Suppl 2:S123–S130. 2009.
|
|
5
|
Jaffe CA: Clinically non-functioning
pituitary adenoma. Pituitary. 9:317–321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Daly AF, Rixhon M, Adam C, Dempegioti A,
Tichomirowa MA and Beckers A: High prevalence of pituitary
adenomas: A cross-sectional study in the province of Liege,
Belgium. J Clin Endocrinol Metab. 91:4769–4775. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greenman Y and Stern N: Non-functioning
pituitary adenomas. Best Pract Res Clin Endocrinol Metab.
23:625–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhan X and Desiderio DM: Signaling pathway
networks mined from human pituitary adenoma proteomics data. BMC
Med Genomics. 3:132010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Indraccolo S, Minuzzo S, Masiero M and
Amadori A: Ligand-driven activation of the notch pathway in T-ALL
and solid tumors: Why Not(ch)? Cell Cycle. 9:80–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Melmed S: Pathogenesis of pituitary
tumors. Nature Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar
|
|
11
|
Bianchi S, Dotti MT and Federico A:
Physiology and pathology of notch signalling system. J Cell
Physiol. 207:300–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai EC: Notch signaling: Control of cell
communication and cell fate. Development. 131:965–973. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greenwald I: LIN-12/Notch signaling:
Lessons from worms and flies. Genes Dev. 12:1751–1762. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Artavanis-Tsakonas S, Matsuno K and
Fortini ME: Notch signaling. Science. 268:225–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moreno CS, Evans CO, Zhan X, Okor M,
Desiderio DM and Oyesiku NM: Novel molecular signaling and
classification of human clinically nonfunctional pituitary adenomas
identified by gene expression profiling and proteomic analyses.
Cancer Res. 65:10214–10222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miao Z, Miao Y, Lin Y and Lu X:
Overexpression of the Notch3 receptor in non-functioning pituitary
tumours. J Clin Neurosci. 19:107–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu R, Gao H, Wang H, Cao L, Bai J and
Zhang Y: Overexpression of the Notch3 receptor and its ligand
Jagged1 in human clinically non-functioning pituitary adenomas.
Oncol Lett. 5:845–851. 2013.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Li Y, Kong D and Sarkar FH: The
role of Notch signaling pathway in epithelial-mesenchymal
transition (EMT) during development and tumor aggressiveness. Curr
Drug Targets. 11:745–751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu XB, Feng F, Wang YC, Wang L, He F, Dou
GR, Liang L, Zhang HW, Liang YM and Han H: Blockade of Notch
signaling in tumor-bearing mice may lead to tumor regression,
progression, or metastasis, depending on tumor cell types.
Neoplasia. 11:32–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roy M, Pear WS and Aster JC: The
multifaceted role of Notch in cancer. Curr Opin Genet Dev.
17:52–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weijzen S, Rizzo P, Braid M, Vaishnav R,
Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC,
et al: Activation of Notch-1 signaling maintains the neoplastic
phenotype in human Ras-transformed cells. Nat Med. 8:979–986. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad
A, Banerjee S, Azmi AS, Miele L and Sarkar FH: Notch-1 induces
epithelial-mesenchymal transition consistent with cancer stem cell
phenotype in pancreatic cancer cells. Cancer Lett. 307:26–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, de Marco MA, Graziani I, Gazdar
AF, Strack PR, Miele L and Bocchetta M: Oxygen concentration
determines the biological effects of Notch-1 signaling in
adenocarcinoma of the lung. Cancer Res. 67:7954–7959. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koch U and Radtke F: Notch and cancer: A
double-edged sword. Cell Mol Life Sci. 64:2746–2762. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Chen C, Hong L, Wang J, Du Y, Song
J, Shao X, Zhang J, Han H, Liu J and Fan D: Expression of Jagged1
and its association with hepatitis B virus X protein in
hepatocellular carcinoma. Biochem Biophys Res Commun. 356:341–347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Purow BW, Haque RM, Noel MW, Su Q, Burdick
MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, et al:
Expression of Notch-1 and its ligands, Delta-Like-1 and Jagged-1,
is critical for glioma cell survival and proliferation. Cancer Res.
65:2353–2363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Somasundaram K, Reddy SP, Vinnakota K,
Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M,
Sreepathi HK, et al: Upregulation of ASCL1 and inhibition of Notch
signaling pathway characterize progressive astrocytoma. Oncogene.
24:7073–7083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maemura K, Yoshikawa H, Yokoyama K, Ueno
T, Kurose H, Uchiyama K and Otsuki Y: Delta-like 3 is silenced by
methylation and induces apoptosis in human hepatocellular
carcinoma. Int J Oncol. 42:817–822. 2013.PubMed/NCBI
|
|
31
|
Chapman G, Sparrow DB, Kremmer E and
Dunwoodie SL: Notch inhibition by the ligand DELTA-LIKE 3 defines
the mechanism of abnormal vertebral segmentation in spondylocostal
dysostosis. Hum Mol Genet. 20:905–916. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loomes KM, Stevens SA, O'Brien ML,
Gonzalez DM, Ryan MJ, Segalov M, Dormans NJ, Mimoto MS, Gibson JD,
Sewell W, et al: Dll3 and Notch1 genetic interactions model axial
segmental and craniofacial malformations of human birth defects.
Dev Dyn. 236:2943–2951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patel NS, Li JL, Generali D, Poulsom R,
Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in
human tumor vasculature and the role of basal expression in
endothelial cell function. Cancer Res. 65:8690–8697. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mailhos C, Modlich U, Lewis J, Harris A,
Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific
notch ligand expressed at sites of physiological and tumor
angiogenesis. Differentiation. 69:135–144. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li JL, Sainson RC, Shi W, Leek R,
Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E,
Hainfellner JA and Harris AL: Delta-like 4 Notch ligand regulates
tumor angiogenesis, improves tumor vascular function, and promotes
tumor growth in vivo. Cancer Res. 67:11244–11253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Djokovic D, Trindade A, Gigante J, Badenes
M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS and Duarte
A: Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy
is highly effective in disrupting tumor angiogenesis. BMC Cancer.
10:6412010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Al Haj, Zen A, Oikawa A, Bazan-Peregrino
M, Meloni M, Emanueli C and Madeddu P: Inhibition of
delta-like-4-mediated signaling impairs reparative angiogenesis
after ischemia. Circ Res. 107:283–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams CK, Li JL, Murga M, Harris AL and
Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits
VEGF-induced endothelial cell function. Blood. 107:931–939. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Weng AP and Aster JC: Multiple niches for
Notch in cancer: Context is everything. Curr Opin Genet Dev.
14:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hellström M, Phng LK, Hofmann JJ, Wallgard
E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N,
et al: Dll4 signalling through Notch1 regulates formation of tip
cells during angiogenesis. Nature. 445:776–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bray SJ: Notch signalling: A simple
pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ladi E, Nichols JT, Ge W, Miyamoto A, Yao
C, Yang LT, Boulter J, Sun YE, Kintner C and Weinmaster G: The
divergent DSL ligand Dll3 does not activate Notch signaling but
cell autonomously attenuates signaling induced by other DSL
ligands. J Cell Biol. 170:983–992. 2005. View Article : Google Scholar : PubMed/NCBI
|
